PREVENTION OF MISCARRIAGE IN ANTIPHOSPHOLIPID SYNDROME

被引：15

作者：

PASSALEVA, A

MASSAI, G

DELIOS, MM

LIVI, C

ABBATE, R

机构：

[1] Clinics Medica III, University of Florence, 50134, Florence

[2] Clinica Ostetrica e Ginecologica, University of Florence, 50134, Florence

[3] Clinica Medica I, University of Florence, 50134, Florence

来源：

AUTOIMMUNITY | 1992年 / 14卷 / 02期

关键词：

ANTIPHOSPHOLIPID ANTIBODIES; RECURRENT ABORTION; THERAPY; ACETYLSALICYLIC ACID; STEROIDS;

D O I：

10.3109/08916939209083130

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recurrent adverse pregnancy outcome may be the final result of different causes, including autoimmune diseases, as the Antiphospholipid Syndrome. Antiphospholipid antibodies (lupus anticoagulant and/or anticardiolipin antibodies) were found in 16% of 197 patients with prior unexplained recurrent miscarriages. During our study 22 out of 32 antiphospholipid antibodies positive women became pregnant again. To prevent abortion relapses, 16 of them were treated with acetylsalicylic acid (50 mgx2/day) and/or fluocortolone (20 mg/day for 5 days/week). Such therapy started as soon as pregnancy was diagnosed in 14 patients. Two patients began the therapeutic regimen during the third month of gestation. Six patients, who didn't accept this therapeutic approach, represent our control group. All the 14 early treated patients ended pregnancy with success. The 2 women that began the therapy later presented abortion relapses. Among the 6 not treated patients, 5 presented spontaneous abortion and only one gave birth to a baby. No side effect was observed neither in treated mothers nor in their babies. In conclusion, even if further studies would be necessary to standardise a therapeutic protocol, our results encourage the clinical care of patients with antiphospholipid antibodies and adverse pregnancy outcomes.

引用

页码：121 / 125

页数：5

共 26 条

[1]

Cameras L.O., Machin S.J., Deman R., Et al., Arterial thrombosis. intrauterine death, and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation, Lancet, 1, pp. 244-246, (1981)

[2]

DeWolf F., Cameras L.O., Moermanp, Et al., Decidual vasculopathy and extensive placental infarction in a patient with throm-boembolic accidents, recurrent fetal loss, and a lupus anticoagulant, Am J Obster Gynecol, 142, pp. 829-834, (1982)

[3]

Branch D.W., Dudley D.J., Murray D., Et al., Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/C mice: a model for autoimmune fetal loss, Am J Ohstet Gynecol, 163, pp. 210-216, (1990)

[4]

Lubbe W.F., Liggins G.C., Lupus anticoagulant, thrombosis, and pregnancy, Am J Obstet Gynecol, 153, pp. 322-327, (1985)

[5]

Parke A., Maier D., Hakim C., Et al., Subclinical autoimmune disease and recurrent spontaneous abortion, J Rheumatol, 13, pp. 1178-1183, (1986)

[6]

Gardlund B., The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus, Acta Med Scand, 215, pp. 293-298, (1984)

[7]

Hellgren M., Tengbum L., Abidgard U., Pregnancy in women with congenital antithrombin III deficiency, Gynecol Obster Invest, 14, pp. 127-141, (1982)

[8]

Reece E.A., Gabrielli S., Harris E.N., Et al., Recurrent adverse pregnancy outcome and antiphospholipid antibodies, Am J Obster Gynecol, 163, pp. 162-169, (1990)

[9]

Harris E.N., Gharavi A.E., Boey M.L., Et al., Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus, Lancet, 2, pp. 1211-1214, (1983)

[10]

Tincani A., Meroni P.L., Brucato A., Et al., Antiphospholipid and anti mitochondryal type M5 antibodies in systemic lupus erythematosus, Clin Exp Rheumatol, 3, pp. 321-326, (1985)

← 1 2 3 →